Kuros Biosciences AG KURN

SWX: KURN | ISIN: CH0325814116   30/04/2026
20,28 CHF (-3,43%)
(-3,43%)   30/04/2026

15 april 2026 · Annual General Meeting of Kuros Biosciences approves all resolutions · Persbericht

14 april 2026 · Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 · Persbericht

10 maart 2026 · Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 · Persbericht

13 januari 2026 · Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences · Persbericht

2 december 2025 · Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion · Persbericht

26 november 2025 · Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference · Persbericht

16 oktober 2025 · Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025 · Persbericht

30 september 2025 · Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 · Persbericht

18 september 2025 · Kuros statement on media inquiry concerning former Board member · Persbericht

4 september 2025 · Kuros Biosciences announces changes in the Board of Directors · Persbericht

14 augustus 2025 · Kuros Biosciences Reports First Half of 2025 Results · Persbericht

5 augustus 2025 · Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance · Persbericht

13 mei 2025 · Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich · Persbericht

15 april 2025 · Annual General Meeting of Kuros Biosciences approves all resolutions · Persbericht

15 april 2025 · Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 · Persbericht

11 maart 2025 · Kuros Biosciences grows sales to CHF 75.6 million for 2024 · Persbericht

Mijn selecties